MALLINCKRODT ALBUNEX TEST MARKETING TO BEGIN IN EARLY SEPTEMBER
This article was originally published in The Gray Sheet
Executive Summary
MALLINCKRODT ALBUNEX TEST MARKETING TO BEGIN IN EARLY SEPTEMBER at 10 hospitals following FDA clearance of the product Aug. 5. The approval is the agency's first for an ultrasound contrast imaging agent for use in the left side of the heart. Albunex was developed by Molecular Biosystems, Inc.; Mallinckrodt Medical has marketing rights in North and South America.